470 filings
Page 2 of 24
6-K
HCM
HUTCHMED (China) Limited
1 Dec 23
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
6:03am
6-K
HCM
HUTCHMED (China) Limited
30 Nov 23
Current report (foreign)
6:09am
6-K
HCM
HUTCHMED (China) Limited
9 Nov 23
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
6:03am
6-K
HCM
HUTCHMED (China) Limited
24 Oct 23
Vesting of awards under the Long Term Incentive Plan
6:19am
6-K
HCM
HUTCHMED (China) Limited
16 Oct 23
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
6:05am
6-K
HCM
HUTCHMED (China) Limited
29 Sep 23
Current report (foreign)
6:20am
6-K
HCM
HUTCHMED (China) Limited
14 Sep 23
Current report (foreign)
6:14am
6-K
HCM
HUTCHMED (China) Limited
12 Sep 23
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
6:10am
UPLOAD
HCM
HUTCHMED (China) Limited
12 Sep 23
Letter from SEC
12:00am
6-K
HCM
HUTCHMED (China) Limited
31 Aug 23
Current report (foreign)
6:04am
6-K
HCM
HUTCHMED (China) Limited
29 Aug 23
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
6:12am
CORRESP
HCM
HUTCHMED (China) Limited
24 Aug 23
Correspondence with SEC
12:00am
6-K
HCM
HUTCHMED (China) Limited
21 Aug 23
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
6:10am
UPLOAD
HCM
HUTCHMED (China) Limited
10 Aug 23
Letter from SEC
12:00am
6-K
HCM
HUTCHMED (China) Limited
7 Aug 23
Current report (foreign)
6:04am
6-K
HCM
HUTCHMED (China) Limited
31 Jul 23
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
7:31am
6-K
HCM
HUTCHMED (China) Limited
20 Jul 23
Current report (foreign)
6:33am
6-K
HCM
HUTCHMED (China) Limited
13 Jul 23
HUTCHMED Announces Changes to Board of Directors and Technical Committee
6:03am
6-K
HCM
HUTCHMED (China) Limited
10 Jul 23
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
6:04am
6-K
HCM
HUTCHMED (China) Limited
29 Jun 23
Current report (foreign)
6:11am